June 5, 2022, Cairo, Egypt - Rusatom Healthcare Joint Stock Company, a single integrator in the field of radiation technologies for medicine and other industries, a daughter company of the Rosatom State Corporation, and the leading Egyptian pharmaceutical company Pharco Pharmaceuticals signed a Memorandum of Understanding. The Memorandum was signed within the framework of the first Pan-African exhibition and conference Africa Health ExCon 2022, dedicated to the healthcare and pharmaceutical market.
The Memorandum confirmed the intentions of the parties regarding the further development of cooperation and the implementation of joint projects. In particular, the parties agreed to work together on projects of joint development and production of radiopharmaceuticals, conducting pre-clinical, clinical studies, registration and launch of developed products to the market of Egypt, Middle East, Eurasian Economic Union and other countries.
Igor Obrubov, General Director of JSC Rusatom Healthcare, noted: "The radiopharmaceutical industry is one of the most dynamically developing areas in medicine today. The reason for this is the high demand for radiopharmaceuticals by Physicians and patients. Radiotherapy is required for the diagnosis and treatment of about 50% of patients with cancer, and about 20 million new cases are detected annually in the world. In addition, radiopharma is actively used in a number of other nosologies: cardiology, rheumatology, endocrinology. With the development of medical science, this list, I am sure, will expand. I am glad that we have found a partner - Pharco Pharmaceuticals with the like-minded leadership represented by Dr.Sherine Helmy and Pharco’s staff. Together we will be able not only to establish efficient production, but also to develop the new drugs that Physicians and patients around the world are very much waiting for."
Dr. Sherine Helmy, CEO of Pharco Pharmaceuticals: “Pharco Pharmaceuticals envisions a great value of cooperation with Rusatom Healthcare in the field of radiopharmaceuticals being a novel field in Egypt with important applications in oncology treatment. We are looking forward to initiate the research and development of new treatment options for oncology patients”.
JSC Rusatom Healthcare is a division accumulating expertise of Rosatom State Corporation in the field of nuclear medicine. The company was established on the basis of Rosatom enterprises and institutes with the aim of comprehensive development of medical technologies in Russia and abroad. Rusatom Healthcare is developing in four main areas: turnkey integrated solutions for medicine; production and supply of isotope products (to 50 countries of the world); development and manufacturing of equipment for diagnostics and therapy; solutions for industrial applications of radiation technologies.
Pharco Pharmaceuticals is a founding corporation and the second privately owned Egyptian pharmaceutical company founded in 1984. It started production in 1987, introducing about 450 brands, generics, branded generics and licensed products to date. Pharco Pharmaceuticals has scientific offices in KSA, Yemen, UAE, Bahrain, Lebanon, Libya and Romania and exports its products to more than 50 countries worldwide.
The first Pan-African exhibition and conference Africa Health ExCon 2022, dedicated to the healthcare and pharmaceutical market, is taking place from June 5 to 7 in Cairo, Egypt. The event is held under the patronage of the President of the Arab Republic of Egypt Abdel Fattah El-Sisi and brings together delegates and participants from more than 100 countries.